Stockscreener 앱 받기
50.46
2.76%
-1.43
시간 외 거래:
50.69
0.23
+0.46%
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics’ Stock Climbing Amid 44-Week Trial Data Buzz - StocksToTrade
William Blair reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Structure Therapeutics (GPCR) Stock Surges 10% as GLP-1 Pill Outperforms Lilly and Novo - CoinCentral
Leerink reiterates Outperform on Structure Therapeutics stock - Investing.com
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results - TipRanks
Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Bitget
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
HighVista Strategies LLC Acquires 149,615 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Pill from Structure Therapeutics helped patients lose about 40 lbs - Stock Titan
First Light Asset Management LLC Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Casdin Capital LLC - MarketBeat
Baker BROS. Advisors LP Sells 952,658 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation After Its Quarterly Profit Turnaround - Sahm
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf RegistrationAnd What's Next - Sahm
Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - Stock Traders Daily
Research Analysts Offer Predictions for GPCR Q1 Earnings - Defense World
Tax withholding trims Structure Therapeutics (NASDAQ: GPCR) CMO stake - Stock Titan
Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes - Stock Titan
Structure Therapeutics (GPCR) CFO logs tax-withholding share disposition - Stock Titan
Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions - Stock Titan
Structure Therapeutics (GPCR) CEO reports tax share withholding and large trust-held stake - Stock Titan
HC Wainwright Issues Negative Estimate for GPCR Earnings - MarketBeat
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - TradingView
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
GPCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Sells 212,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT) - The Globe and Mail
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
H.C. Wainwright raises Structure Therapeutics price target on competitive positioning - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Monashee Investment Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BrightSpring Health Services, Inc. (BTSG) - The Globe and Mail
Did New Shelf Registration and Oral GLP-1 Progress Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Intellia Therapeutics (NTLA) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - Defense World
Structure Therapeutics shares could rise on obesity drug data, Cantor says - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp - MarketBeat
Citizens cuts Structure Therapeutics stock price target on pipeline expansion - Investing.com
Structure Therapeutics shares could rise on obesity drug data, Cantor says By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Structure Therapeutics Inc. SEC 10-K Report - TradingView
Structure Therapeutics (NASDAQ: GPCR) turns Q4 profit as obesity pipeline advances - Stock Titan
Obesity pill aleniglipron trims 15% weight as maker turns quarterly profit - Stock Titan
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):